Difference between revisions of "Rituximab-arrx (Riabni)"

Revision as of 13:21, 7 June 2023

Note: this is an FDA-approved biosimilar. The information below is reproduced from the Rituximab (Rituxan) page, except for the details of FDA indication.

General information

Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
Route: IV
Extravasation: neutral

Rituximab (Rituxan) desensitization protocol

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

Patient drug information

History of changes in FDA indication

To be completed

Also known as

Brand names: Riabni

References

[1] Rituximab (Rituxan) patient drug information (Chemocare)

[2] Rituximab (Rituxan) patient drug information (UpToDate)

[1]

[2]

@@ Line 74: / Line 74: @@
 [[Category:Post-transplant lymphoproliferative disorder medications]]
 [[Category:Primary mediastinal B-cell lymphoma medications]]
-[[Category:Thrombotic thrombocytopenic purpura medications]]
+[[Category:Acquired thrombotic thrombocytopenic purpura medications]]
 [[Category:Transformed lymphoma medications]]
 [[Category:Waldenström macroglobulinemia medications]]